glp-1/glp-2 dual agonist The current significance and prospects for the use of receptor agonism GLP-1/Glucagon Managing symptoms with GLP-1 receptor
Description
10.1038/s41588-018-0332-4 94 TangC.AhmedK.GilleA.LuS.GrneH
Gynecol Oncol

IDF Diabetes Atlas 9th Edition

Regarding night sweats specifically , this symptom is not listed as a recognized side effect in the FDA-approved prescribing information for any GLP-1 receptor agonist or tirzepatide

FDA approval expected 2025-2026 will make pharmaceutical-grade cagrilintide and CagriSema widely accessible, though research peptides currently provide the same compounds for those willing to self-administer

Retrieved from MedlinePlus
